Cynata Receives $1.88m R&D Tax Incentive Refund
Filed with ASX · · 1 page · English
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- Study of Cymerus MSCs in Pulmonary Fibrosis Published
- Cynata to Acquire IP from Tekcyte
- Further GvHD Clinical Data Published in Nature Medicine
- DFU Clinical Trial Enrolment Complete
- EU Approval for Phase 2 CYP-001 Trial in GvHD
Later from Cynata Therapeutics
- Trading Halt
- Demonstrated Safety & Efficacy in DFU Clinical Trial
- Cynata secures commitments for $8.1m institutional placement
- First Kidney Transplant Trial Patient Treated
- Quarterly Activity Report & Appendix 4C
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics